Application of drug delivery system to boron neutron capture therapy for cancer
Application of drug delivery system to boron neutron capture therapy for cancer
复制标题
DOI：
10.1517/17425247.5.4.427
复制
发表时间：
2008-04
影响因子：
6.6
通讯作者：
H. Yanagië;A. Ogata;H. Sugiyama;M. Eriguchi;Shinichi Takamoto;Hiroyuki Takahashi
中科院分区：
文献类型：
--
作者：
H. Yanagië;A. Ogata;H. Sugiyama;M. Eriguchi;Shinichi Takamoto;Hiroyuki Takahashi
背景资料：硼中子俘获治疗（BNCT）中肿瘤细胞的破坏是由于10 B与热中子（10 B +1 n → 7 Li +4 He（α）+2.31 MeV（93.7%）/2.79 MeV（6.3%））之间的核反应。由此产生的锂离子和α粒子是高线性能量传递（LET）粒子，其产生高生物效应。它们在组织中的短距离（5 - 9 μm）限制了中子辐照时硼原子所在细胞的辐射损伤。BNCT在临床上已应用于恶性脑肿瘤、恶性黑色素瘤、头颈部肿瘤和肝癌的治疗。巯基十一氢十二硼酸钠（Na 210 B12 H11 SH：BSH）和硼基苯丙氨酸（10 BPA）目前正用于临床治疗。这些低分子化合物很容易从癌细胞和血液中清除，因此硼化合物在肿瘤组织和癌细胞中的高积累和选择性递送对于实现有效的BNCT和避免损伤邻近的健康细胞是最重要的。目的：为了实现硼原子向癌细胞的选择性递送，药物递送系统（DDS）是一种具有吸引力的靶向和控制释放药物的智能技术。研究方法：我们进行了文献检索相关的硼输送系统在体外和体内结果：我们描述了几个DDS技术硼输送到癌组织和癌细胞从过去到现在的状态。我们相信，按照良好商业产品（GCP）级材料的制备，将有可能使用脂质体、单克隆抗体和WOW乳剂作为BNCT的硼递送系统。
Background: Tumor cell destruction in boron neutron capture therapy (BNCT) is due to the nuclear reaction between 10B and thermal neutrons (10B + 1n → 7Li + 4He (α) + 2.31 MeV (93.7 %)/2.79 MeV (6.3 %)). The resulting lithium ions and αparticles are high linear energy transfer (LET) particles which give a high biological effect. Their short range in tissue (5 – 9 μm) restricts radiation damage to those cells in which boron atoms are located at the time of neutron irradiation. BNCT has been applied clinically for the treatment of malignant brain tumors, malignant melanoma, head and neck cancer and hepatoma. Sodium mercaptoundecahydro-dodecaborate (Na210B12H11SH: BSH) and borono-phenylalanine (10BPA) are currently being used in clinical treatments. These low molecule compounds are easily cleared from cancer cells and blood, so high accumulation and selective delivery of boron compounds into tumor tissues and cancer cells are most important to achieve effective BNCT and to avoid damage to adjacent healthy cells. Objective: In order to achieve the selective delivery of boron atoms to cancer cells, a drug delivery system (DDS) is an attractive intelligent technology for targeting and controlled release of drugs. Methods: We performed literature searches related to boron delivery systems in vitro and in vivo Results: We describe several DDS technologies for boron delivery to cancer tissues and cancer cells from the past to current status. We are convinced that it will be possible to use liposomes, monoclonal antibodies and WOW emulsions as boron delivery systems for BNCT clinically in accordance with the preparation of good commercial product (GCP) grade materials.